Recent News

• 04.03.2025 - Clinical Project Manager
• 04.03.2025 - VP, Head of Biometrics
• 03.26.2025 - Medical Director
• 03.26.2025 - Director of Clinical Data Management
• 03.18.2025 - Stifel 2025 Virtual CNS Forum
• 03.17.2025 - Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
• 03.12.2025 - Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
• 03.11.2025 - Leerink Partners Global Healthcare Conference
• 03.06.2025 - Active MS lesions are characterized by high LPA1 expression and PIPE-791 promotes remyelination via LPA1 inhibition in the cuprizone model
• 03.06.2025 - Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Recent Filings

• 03.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - 8-K Current report
• 03.17.2025 - 3 Initial statement of beneficial ownership of securities
• 03.06.2025 - EX-99.1 EX-99.1
• 03.06.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.06.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.06.2025 - 8-K Current report
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors